Biopharma experts knew that 2024 was unlikely to be the year that pharma came roaring back in a blaze of mega-mergers, high profile IPOs and eye-watering private investment rounds. And looking back on the year, at least we can say we didn’t get our hopes up too much, despite what looked like a promising start.
But was 2024 a damp squib? Or was it as much as we could reasonably expect after the pain of 2023? In this 2024 review of pharma, we look at the dealmaking and investment landscape of the past 12 months, seek out the highs and lows, and consider what it means for the year ahead.
We investigate:
- The state of M&A though the year
- The shaky start of an IPO comeback for biopharma
- A boost to VC fundraising
- The winners and losers on the stock market
